Compare Gerdau S.A. Common Stock (GGB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Gerdau S.A. Common Stock trades at $5.15 (market cap $9.66B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Gerdau S.A. Common Stock is the larger of the two by market cap, and Gerdau S.A. Common Stock pays a 3.48% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GGB | SYRE | |
|---|---|---|
Market Cap | $9.66B | $7.52B |
Volume | 9,572,970 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $5.18 | $108.92 |
52-Week Low | $3.25 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.61B | $6.52B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gerdau (GGB) trades at $5.18, up 0.78% with strong technical momentum and bullish moving average signals. The company reported mixed Q2 2026 earnings meeting expectations but missed previous quarters, while showing improved profitability with net income margin expanding to 3.23%. Recent news highlights institutional buying interest and dividend appeal, with the stock approaching its 52-week high of $5.48.
GGB presents a value opportunity with attractive valuation multiples (P/S 0.73, P/B 0.95) and strong analyst support (70% buy ratings). However, recent earnings misses and competitive pressures in Brazilian operations pose execution risks. The improving cash flow trajectory and institutional accumulation suggest potential upside if operational improvements continue.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
